Matritech bladder cancer test detected 100% of tumors in at-risk women

By Elaine Rigoli

Tampa, Fla., March 24 - Matritech, Inc. said its NMP22 BladderChek test detected 100% of the aggressive tumors, one of which was muscle invasive, in women with symptoms or risk factors for bladder cancer.

The test was also positive for seven conditions that required biopsy for diagnosis, according to a news release.

This test has the potential to be an effective screening tool in identifying aggressive lesions early and improving prognosis in women at risk for bladder cancer, officials said.

In other clinical studies it was shown to be an effective adjunctive tool in the diagnosis and monitoring of bladder cancer - improving cancer detection to 99%, the release said.

Matritech developed the NMP22 BladderChek test to detect elevated levels of the NMP22 protein marker in a single urine sample. The test, a painless and noninvasive assay, is the only in-office test approved by the Food and Drug Administration for the diagnosis of bladder cancer, the release said.

Newton, Mass.-based Matritech develops protein-based diagnostic products for the early detection of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.